Eisai and Biogen today announced the decision to discontinue the global phase III trials, ENGAGE and EMERGE, that was designed to measure efficacy and safety of aducanumab. We are somewhat surprised that any information would get presented at this time. Of the failed phase III trials with Aβ immunotherapies so far, aducanumab is most similar to ALZ-101. From this point of view, it is to be seen as negative news. However, there was limited information on today’s decision to discontinue development with aducanumab. Investors should hence take a cautious stance until more information presents. It is to be noted that ALZ-101 and aducanumab have distinct differences as well.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se